No profile data available.
Minerva Neurosciences, Inc. (NERV) is a healthcare company in the brain and nerve treatment drugs industry, based in Burlington, United States, with about 7 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$293.42 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $151.84 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc.
Minerva Neurosciences reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$151.84 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Inhibikase Therapeutics, Inc. (IKT), PepGen Inc. (PEPG), Acumen Pharmaceuticals, Inc. (ABOS), Voyager Therapeutics, Inc. (VYGR).